Related Experiment Video
Updated: Jul 3, 2026
08:02
Mouse Model of Surgically-induced Endometriosis by Auto-transplantation of Uterine Tissue
Published on: January 6, 2012
Combating endometriosis by blocking proteasome and nuclear factor-kappaB pathways
Onder Celik1, Seyma Hascalik, Koray Elter
1Department of Obstetrics and Gynecology, Inonu University School of Medicine, 44069, Malatya, Turkey. oncelik@inonu.edu.tr
Human Reproduction (Oxford, England)
|August 5, 2008
Summary
Pyrrolidine dithiocarbamate (PDTC) and bortezomib effectively reduced experimental endometriosis in rats. These nuclear factor-kappaB and proteasome inhibitors decreased implant size and cell proliferation, suggesting a new therapeutic approach for endometriosis.
Area of Science:
- Reproductive biology
- Pharmacology
- Oncology
Background:
- Endometriosis is a condition where uterine tissue grows outside the uterus.
- Current treatments for endometriosis have limitations.
- Novel therapeutic strategies are needed to manage endometriosis effectively.
Purpose of the Study:
- To investigate the efficacy of pyrrolidine dithiocarbamate (PDTC) and bortezomib in treating experimental endometriosis in a rat model.
- To assess the impact of these agents on endometriotic implant development and cellular markers.
Main Methods:
- Surgically induced endometriosis in 30 rats.
- Administered PDTC and bortezomib to treatment groups, with a control group.
- Measured implant volume and assessed expression of Ki67, PCNA, CD34, CD31, and Masson's trichrome post-treatment.
Main Results:
- PDTC and bortezomib significantly reduced endometriotic implant volumes compared to controls (P < 0.002 and P < 0.001, respectively).
- Treatment decreased the incidence of larger vesicles (Grades 3 and 4) and increased Grade 1 (no vesicle).
- Reduced expression of proliferation markers (Ki67, PCNA) and angiogenesis markers (CD34, CD31) was observed in treated groups.
Conclusions:
- PDTC and bortezomib demonstrate significant therapeutic potential for endometriosis.
- These agents may offer a novel treatment strategy by inhibiting implant growth and vascularization.
- Further research is warranted to explore their clinical application in endometriosis management.
Related Concept Videos
01:13The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
02:18The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...